NCT02248961已完成3 期
Open-label, Randomized, Multicenter, Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan), Manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, Tablets 60/120 mg and Cozaar® (Losartan), Manufactured by MERCK SHARP & DOHME B.V., Netherlands, Tablet 50/100 mg in Adult Patients With Grade I-II Arterial Hypertension
R-Pharm13 个研究点 分布在 1 个国家目标入组 179 人开始时间: 2014年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 179
- 试验地点
- 13
- 主要终点
- Change in Systolic Blood Pressure (SBP) After 12 Weeks of Treatment
研究概览
简要总结
Assess and compare the efficacy and safety of Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg and Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablet 50/100 mg in adult patients with Grade I-II arterial hypertension in 12 weeks of therapy
详细描述
- To evaluate efficacy of 12-week Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg and Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablet 50/100 mg in adult patients with Grade I-II arterial hypertension.
- To evaluate safety of 12-week Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg and Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablet 50/100 mg in adult patients with Grade I-II arterial hypertension.
- Assess the pharmacokinetics parameters of Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea in adult patients with arterial hypertension I-II stage after a single dose.
Starting dose of Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea is 60 mg, orally, once a day in the morning.
The planned study duration for each subject is 18 weeks maximum:
The screening period could takes up to 2 weeks (including the 1-week "wash-out" period ) - the screening period duration depends on the prior anti-hypertensive therapy:
- "naive" subjects who never received therapy (which must be reflected in the source documents), may be randomized after completion of all screening procedures;
- Subjects receiving anti-hypertensive therapy which may be discontinued without prior dose reduction must undergo a 7 days "wash-out" period, so the screening period will take at least 7 days;
- Subjects, receiving anti-hypertensive therapy which requires dose reduction before discontinuation must undergo the 7 days "wash-out" period after the last dose administration, so the screening period will consist of dose reduction period and a "wash-out" period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of both sex aged 18-75 inclusively.
- •Subjects who signed their written Informed Consent for participation in the study and willing to adhere to all Protocol procedures.
- •Subjects with documented diagnosis of grade I-II primary arterial hypertension within at least 3 months before screening.
- •Systolic blood pressure (SBP) (when seated) at Screening (Day -14)
- •For subjects administered with anti-hypertensive therapy: SBP ≤ 179 Hg
- •For subjects receiving no anti-hypertensive therapy (so called 'naïve' patients): 140≥SBP ≤
- •As per investigator's judgment, subjects with controlled arterial hypertension must benefit from the therapy switch to Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg and Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, .
- •For subjects administered with anti-hypertensive drugs: the anti-hypertensive drug may be safely cancelled during the "wash-out" period according to the investigator's judgment.
- •For women of child-bearing potential: negative urine pregnancy test at screening (Day -14).
- •Systolic blood pressure (SBP) (when seated) at Randomization (Day 0) ≥140 mmHg and ≤179 mmHg.
- •For women of child-bearing potential: negative urine pregnancy test at Randomization (Day 0)
排除标准
- •Grade III Arterial Hypertension.
- •Arterial hypotension (SPB ≤100 mm Hg) at Screening (Day -14) and/or Randomization (Day 0).
- •Subjects needing treatment with more than one anti-hypertensive drug (more than one active substance, including complex drugs).
- •Secondary (symptomatic) arterial hypertension.
- •Known bilateral renal arterial stenosis or unilateral renal arterial stenosis.
- •Hyperpotassemia >5,0 mmol/l (as per blood biochemistry results at Screening).
- •Primary hyperaldosteronism.
- •Known hypersensitivity to angiotensin-II receptors antagonists or any other study drug or comparator component.
- •Contraindications for use of angiotensin-II receptors antagonists.
- •Myocardial infarction and or unstable angina, and/or acute cerebrovascular accident/transient ischemic attack, and/or percutaneous coronary intervention, and/or coronary arterial bypass graft, acute coronary arteries involvement, and/or obliterative vascular atherosclerosis of low extremities, and/or grade III and IV retinopathy in anamnesis.
- •Clinically significant cardiac valves damage.
- •Cardiomyopathies
- •Chronic Heart failure (CHF) (except for CHF FC I NYHA).
- •Creatinine clearance less than 60 ml/min/1.73m2 calculated by Cockroft-Gault formula.
- •Known moderate to severe hepatic insufficiency and/or transaminase increase: AST and/or ALT ≥2*ULN.
- •History of infections (HIV, hepatitis B or C, syphilis).
- •Uncontrolled Diabetes mellitus, Glycosylated hemoglobin level (HbA1c) >7%.
- •Severe systemic diseases, such as gastro-intestinal tract diseases, autoimmune disorders, blood disorders and other conditions which may affect on the study drugs' absorption, distribution and and excretion.
- •Clinically significant abnormalities of laboratory parameters.
- •Drug or alcohol addiction, psychiatric disorders.
- •Medical history of oncological disease within 5 years before screening.
- •Subjects with biliary tracts obstruction.
- •Subjects with genetic disorders, such as galactose intolerance, congenital lactase insufficiency and glucose-galaclose malabsorption syndrome.
- •Any other acute disease or progression and/or decompensation at the moment of enrollment
- •Necessity to administer or administration of prohibited concomitant drugs from the "List of Prohibited Drugs" within 14 days before enrollment
- •Pregnancy or breast-feeding period; fertile women not using adequate contraception methods
- •Participation in another clinical trial within 3 months before Screening.
- •Other medical or psychiatric conditions or lab abnormalities that may increase potential risk associated with study participation and IP administration, or that may affect study results interpretation and as per investigator's judgment, make the subject ineligible.
- •Study site personnel or Sponsor's representatives immediately involved in the study.
- •Subjects, excluded from the study may not be included in it again.
研究组 & 干预措施
Kanarb (Fimasartan)
Experimental
88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
干预措施: Fimasartan (Drug)
Cozaar® (Losartan)
Active Comparator
88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
干预措施: Losartan (Drug)
结局指标
主要结局
Change in Systolic Blood Pressure (SBP) After 12 Weeks of Treatment
时间窗: Baseline and week 12 of treatment
The value of SBP (seated) to be registered was mean of the 3 measurements performed with interval no less than 1 minute using the manual (mercury or mechanic) tonometer after 5 minutes rest. "Change" was calculated as (Value of SBP at week 12 minus Value of SBP at baseline).
次要结局
- Change in DBP After 12 Weeks of Treatment(Baseline and week 12 of treatment)
- Change in SBP After 4 Weeks of Treatment(Baseline and week 4 of treatment)
- Change in SBP After 8 Weeks of Treatment(Baseline and week 8 of treatment)
- Number of Subjects Who Responded on Therapy(Week 12 of treatment)
- Change in Diastolic Blood Pressure (DBP) After 4 Weeks of Treatment(Baseline and week 4 of treatment)
- Change in DBP After 8 Weeks of Treatment(Baseline and week 8 of treatment)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
3 期
The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential HypertensionHypertensionNCT01135212Boryung Pharmaceutical Co., Ltd290
已完成
1 期
A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male VolunteersEssential HypertensionNCT00938132Boryung Pharmaceutical Co., Ltd15
已完成
3 期
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and DyslipidemiaEssential Hypertension, DyslipidemiaNCT02166814Boryung Pharmaceutical Co., Ltd140
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese ParticipantsHealthy VolunteersNCT04497883Shire24
已完成
3 期
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsHypertensionNCT00922480Boryung Pharmaceutical Co., Ltd506